AbCheck Licenses CELEXION Yeast Display Technology for an Industry First
(Thomson Reuters ONE) -
AbCheck s.r.o. /
AbCheck Licenses CELEXION Yeast Display Technology for an Industry First
Processed and transmitted by Thomson Reuters.
The issuer is solely responsible for the content of this announcement.
The first human antibody discovery specialist combining yeast and phage
technologies
Plzen, Czech Republic; March 14, 2011: AbCheck s.r.o., the multi antibody
discovery platforms company, announced today the company has licensed a proven
antibody yeast display technology from CELEXION LLC (Cambridge, MA, USA). The
addition of this platform to AbCheck's current phage display platform places the
company as the World's only antibody discovery specialist leveraging the
advantage of working with both phage and yeast display technologies.
"In our discussions with partners we noticed an increasing demand for human
antibodies with not only high affinity and target specificities, but also good
drugability and biological functionalities," said Dr. Volker Lang, CEO of
AbCheck. "By combining the strength of both yeast and phage technologies into
AbSieve we have created a platform that exactly addresses this market need.
Moreover, we can combine this with delivery in very competitive timeframes and
maximum flexibility to construct generous tailor made deals."
Under the deal terms, AbCheck receives non-exclusive rights to the yeast display
platform in the Czech Republic and worldwide rights to commercialize derivative
products. Financial terms were not disclosed. The technology has proven to be
able to display full length functional IgGs, tandem scFvs and scFvs plus many
other non-antibody proteins.
"We are very pleased to partner with the experienced antibody engineering team
at AbCheck, and to see our powerful SECANT platform become a key component of
their toolbox." said Dr. Brian M. Baynes, CEO of CELEXION.
"In more than 25 projects we have used our phage display antibody technology to
identify human antibodies with high affinities and demanding target
specificities. I am excited about expanding our capabilities by adding the
ability to display antibodies in virtually any format and simultaneously screen
for high affinity and drugability to our already efficient technology," stated
Dr. Vera Molkenthin, CSO of AbCheck. "Now we have the maximum likelihood to
identify antibodies with exactly the drug target profile requested by our
partners."
For further information:
AbCheck MC Services
Dr. Volker Lang Anne Hennecke
Phone: +420 378 051500
Phone: +49 89 210 228 18
Email: v.lang(at)abcheck.eu
Email: anne.hennecke(at)mc-services.eu
About CELEXION
CELEXION LLC is a bioengineering company that develops powerful platform
technologies and products for partners in the pharmaceutical, industrial,
agricultural, and life science research sectors. One of the company's core
technologies is a high-throughput protein engineering system called the SECANT
platform, which enables large libraries of complex proteins to be displayed on
the surface of eukaryotic cells and rapidly interrogated for useful properties.
Other technologies CELEXION has developed include a human, full length IgG
antibody library for biotherapeutic lead generation; enzymatic pathways for
synthesis of a variety of high-value materials from sugar; and a novel set of
enzymes for manipulation of chromosome-sized DNA. The company is based in
Cambridge, MA, USA and financed by Flagship Ventures and GE Healthcare Financial
Services. For further information, please visit our website at
www.celexionbio.com.
CELEXION is a registered trademark and SECANT is a pending trademark application
of Celexion LLC.
About AbCheck
AbCheck s.r.o. focuses on the discovery of human antibodies for partner
companies. Using the yeast display platform AbCheck is able to perform lead
optimisation on any antibody, including antibodies generated from our three
highly validated phage display libraries. This approach enables AbCheck to
deliver antibodies that meet exactly the drug profile requested by our partners.
Additionally, AbSieve, the combined phage and yeast display platforms, is used
to develop antibodies in all antibody formats including full length IgGs as well
as customer specific and novel antibody formats. AbSieve antibodies have
improved drugability through screening in the final antibody drug format
combined with systems that select for highly expressing and stable molecules.
Ultimately, AbSieve antibodies have a higher probability of reaching the market.
AbCheck is recognised for its expertise in antibody discovery throughout the US
and Europe. For further information please visit: www.abcheck.eu.
--- End of Message ---
AbCheck s.r.o.
Press release (PDF):
http://hugin.info/143842/R/1496580/432316.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: AbCheck s.r.o. via Thomson Reuters ONE
[HUG#1496580]
Unternehmensinformation / Kurzprofil:
Datum: 14.03.2011 - 08:00 Uhr
Sprache: Deutsch
News-ID 52399
Anzahl Zeichen: 6217
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 246 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"AbCheck Licenses CELEXION Yeast Display Technology for an Industry First"
steht unter der journalistisch-redaktionellen Verantwortung von
AbCheck s.r.o. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
